CASI Pharmaceuticals Inc.:
Commercially launched EVOMELA® (melphalan for injection: multiple myeloma) on Aug 8, 2019; NMPA review in progress for ZEVALIN® and MARQIBO® (in-licensed from Spectrum). Recently (2Q19) acq'd exclusive WW rights to commercialize anti-CD19 T-cell therapy (CNCT19) in China as well as exclusive WW rights to novel anti-CD38 mAb (CID-103). Acq'd 25 US FDA-approved ANDAS from Sandoz in Jan 2018.
100MM - 500MM
9620 Medical Center Drive
Rockville, MD 20850
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by